

Samir Jana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3891126/publications.pdf>

Version: 2024-02-01

16
papers

583
citations

840776

11
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

1114
citing authors

#	ARTICLE	IF	CITATIONS
1	CXCL13 and CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 265-276.	2.5	106
2	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 8267-8271.	13.8	97
3	Notch signaling in breast cancer: From pathway analysis to therapy. <i>Cancer Letters</i> , 2019, 461, 123-131.	7.2	69
4	miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP. <i>Biochemical and Biophysical Research Communications</i> , 2017, 482, 126-133.	2.1	50
5	SOX9: The master regulator of cell fate in breast cancer. <i>Biochemical Pharmacology</i> , 2020, 174, 113789.	4.4	47
6	Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer. <i>Carcinogenesis</i> , 2021, 42, 38-47.	2.8	46
7	MicroRNA-222 reprogrammed cancer-associated fibroblasts enhance growth and metastasis of breast cancer. <i>British Journal of Cancer</i> , 2019, 121, 679-689.	6.4	40
8	Cooperative involvement of NFAT and SnoN mediates transforming growth factor- β^2 (TGF- β^2) induced EMT in metastatic breast cancer (MDA-MB 231) cells. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 1019-1031.	3.3	28
9	MiR-19b non-canonical binding is directed by HuR and confers chemosensitivity through regulation of P-glycoprotein in breast cancer. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2018, 1861, 996-1006.	1.9	27
10	TGF- β^2 -Smad2 dependent activation of CDC 25A plays an important role in cell proliferation through NFAT activation in metastatic breast cancer cells. <i>Cellular Signalling</i> , 2014, 26, 240-252.	3.6	20
11	Ein Organoruthenium-Tumorthapeutikum mit unerwartet hoher Selektivität für Plectin. <i>Angewandte Chemie</i> , 2017, 129, 8379-8383.	2.0	14
12	Therapeutic targeting of miRNA-216b in cancer. <i>Cancer Letters</i> , 2020, 484, 16-28.	7.2	12
13	Acetylacetonato chelated ruthenium organometallics incorporating imine-phenol function: Spectroscopic, structural, electrochemical and cytotoxicity studies. <i>Inorganica Chimica Acta</i> , 2015, 430, 36-45.	2.4	8
14	Cloning and expression of α -amylase in <i>E. coli</i> : genesis of a superior biocatalyst for substrate-specific MFC. <i>International Journal of Green Energy</i> , 2019, 16, 309-316.	3.8	8
15	Association of TGF- β^1 Polymorphisms with Breast Cancer Risk: A Meta-Analysis of Case-Control Studies. <i>Cancers</i> , 2020, 12, 471.	3.7	5
16	Innenrücktitelbild: Ein Organoruthenium-Tumorthapeutikum mit unerwartet hoher Selektivität für Plectin (<i>Angew. Chem.</i> 28/2017). <i>Angewandte Chemie</i> , 2017, 129, 8415-8415.	2.0	0